Compile Data Set for Download or QSAR
Report error Found 90 Enz. Inhib. hit(s) with all data for entry = 7252
TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184589(US9155743, 18)
Affinity DataIC50: 100nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184594(US9155743, 24)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184602(US9155743, 32)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184610(US9155743, 41)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184601(US9155743, 31)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184600(US9155743, 30)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184599(US9155743, 29)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184598(US9155743, 28)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184576(US9155743, 6)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184597(US9155743, 27)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184616(US9155743, 2)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184596(US9155743, 26)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184575(US9155743, 5)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184593(US9155743, 23)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184592(US9155743, 22)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184617(US9155743, 21)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184590(US9155743, 19)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184574(US9155743, 4)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184614(US9155743, 45 | US9155743, 46)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184609(US9155743, 39)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184584(US9155743, 14)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184581(US9155743, 11)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184614(US9155743, 45 | US9155743, 46)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184609(US9155743, 39)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184584(US9155743, 14)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184595(US9155743, 25)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184608(US9155743, 38)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184611(US9155743, 42)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184607(US9155743, 37)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184583(US9155743, 13)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184582(US9155743, 12)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184614(US9155743, 45 | US9155743, 46)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184577(US9155743, 7)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184606(US9155743, 36)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184618(US9155743, 40)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184572(US9155743, 3)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184580(US9155743, 10)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184605(US9155743, 35)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184579(US9155743, 9)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184604(US9155743, 34)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184578(US9155743, 8)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184599(US9155743, 29)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184605(US9155743, 35)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184579(US9155743, 9)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184604(US9155743, 34)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184578(US9155743, 8)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184575(US9155743, 5)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184595(US9155743, 25)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184601(US9155743, 31)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

TargetE3 ubiquitin-protein ligase XIAP(Human)
Astex Therapeutics

US Patent
LigandPNGBDBM184600(US9155743, 30)
Affinity DataIC50: 505nMpH: 7.5 T: 2°CAssay Description:Modified SMAC peptides and compounds were tested for their ability to displace the fluorescent tracer from either XIAP, cIAP-1 or cIAP-2. BIR3 domain...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2016
Entry Details
Go to US Patent

Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: